Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors

被引:46
|
作者
Zortea, Karine [1 ,2 ]
Franco, Viviane C. [1 ,2 ]
Francesconi, Lenise P. [1 ,2 ]
Cereser, Keila M. M. [1 ,2 ]
Lobato, Maria Ines R. [1 ,2 ]
Belmonte-de-Abreu, Paulo S. [1 ,2 ]
机构
[1] Hosp Clin Porto Alegre, Schizophrenia Program, BR-90035903 Porto Alegre, RS, Brazil
[2] Univ Fed Rio Grande do Sul, Postgrad Program Med Psychiat, BR-90035903 Porto Alegre, RS, Brazil
来源
NUTRIENTS | 2016年 / 8卷 / 02期
关键词
cardiovascular disease; cholesterol; resveratrol; schizophrenia; METAANALYSIS;
D O I
10.3390/nu8020073
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Patients with schizophrenia (SZ) are generally overweight or obese and have several metabolic disorders. Additionally, such patients have a lower life expectancy and the main cause of their increased mortality is cardiovascular disease (CVD). The objective of this study was to determine the efficacy of resveratrol supplementation on serum glucose and CVD risk factors in individuals with SZ. Methods and Results: This is a four-week randomized, double-blind controlled trial (registration No.: NCT 02062190) in which 19 men with a diagnosis of SZ, aged 18 to 65, were assigned to either a resveratrol supplement group (200 mg/day) or a placebo group (200 mg/day). In short, we did not observe significant changes after resveratrol supplementation. In the placebo group, we found a significant increase in total cholesterol levels (p = 0.024) and in LDL-cholesterol (p = 0.002), as well as a decrease in body fat percentage (p = 0.038). The placebo group also showed an increase in triglycerides (9.19%) and a reduction in HDL-cholesterol (4.88%). In the resveratrol group, triglycerides decreased (7.64%). Conclusion: In summary, oral resveratrol in reasonably low dosages (200 mg daily) brought no differences to body weight, waist circumference, glucose, and total cholesterol. It was possible to note that the lipid profile in the placebo group worsened and, although no significant differences were found, we can assume that resveratrol might prevent lipid profile damage and that the intervention affected the lipoprotein metabolism at various levels.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] The effect of almonds on vitamin E status and cardiovascular risk factors in Korean adults: a randomized clinical trial
    Hana Jung
    C.-Y. Oliver Chen
    Jeffrey B. Blumberg
    Ho-Kyung Kwak
    European Journal of Nutrition, 2018, 57 : 2069 - 2079
  • [32] Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial
    Ley, Chit Moy
    Ni Qing
    Liao Xing
    Gao Huai-lin
    Robinson, Nicola
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2016, 22 (10) : 728 - 737
  • [33] Contributions of vitamin D in the management of depressive symptoms and cardiovascular risk factors: study protocol for a randomized, double-blind, placebo-controlled clinical trial
    Porto, Catarina Magalhaes
    Santana Silva, Tatiana de Paula
    Sougey, Everton Botelho
    TRIALS, 2019, 20 (01)
  • [34] The Effects of Resveratrol in a Randomized Clinical Trial on Drug-Induced Hyperlipidemia and Psychiatric Factors in People Living with HIV
    Ahmadi-Mousavi, Bahar
    Karami-Mohajeri, Somayyeh
    Dabaghzadeh, Fatemeh
    Soltani, Motahareh
    Oghabian, Zohreh
    Sharifi, Hamid
    CURRENT HIV RESEARCH, 2024, 22 (06) : 417 - 424
  • [35] Cardiovascular risk factors among patients with schizophrenia, bipolar, depressive, anxiety, and personality disorders
    Perez-Pinar, M.
    Mathur, R.
    Foguet, Q.
    Ayis, S.
    Robson, J.
    Ayerbe, L.
    EUROPEAN PSYCHIATRY, 2016, 35 : 8 - 15
  • [36] A Prospective Randomized Controlled Trial of the Effects of Vitamin D Supplementation on Cardiovascular Disease Risk
    Gepner, Adam D.
    Ramamurthy, Rekha
    Krueger, Diane C.
    Korcarz, Claudia E.
    Binkley, Neil
    Stein, James H.
    CIRCULATION, 2011, 124 (21)
  • [37] Effects of vitamin D supplementation on cardiovascular risk factors in shift workers Study protocol for randomized, double-blind, placebo-controlled clinical trial
    Fajardo, Virginia Capistrano
    Pereira de Oliveira, Fernando Luiz
    Lins Machado-Coelho, George Luiz
    Pedrosa Pimenta, Fausto Aloisio
    de Freitas, Silvia Nascimento
    Pinho Ribeiro, Antonio Luiz
    Sarquis Soares, Maria Marta
    Lauria, Marcio Weissheimer
    Farias, Rosielle da Costa
    Franca, Ive Bahia
    do Nascimento Neto, Raimundo Marques
    MEDICINE, 2019, 98 (18)
  • [38] Immunomodulatory Effects of Probiotic Supplementation in Schizophrenia Patients: A Randomized, Placebo-Controlled Trial
    Tomasik, Jakub
    Yolken, Robert H.
    Bahn, Sabine
    Dickerson, Faith B.
    BIOMARKER INSIGHTS, 2015, 10 : 47 - 54
  • [39] The Relationship of Ten-Year Cardiovascular Disease Risk and Clinical Features in Patients with Schizophrenia
    Kapici, Yasar
    Guc, Bulut
    Tekin, Atilla
    Abus, Sabri
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2023, 60 (03): : 231 - 235
  • [40] Effects of Pomegranate Juice on Cardiovascular Risk Factors in Patients with Metabolic Syndrome: a Double-Blinded, Randomized Crossover Controlled Trial
    Moazzen, Hossein
    Alizadeh, Mohammad
    PLANT FOODS FOR HUMAN NUTRITION, 2017, 72 (02) : 126 - 133